A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers

Changchun Lai
Department of Clinical Laboratory, Maoming People's Hospital, Maoming, 525000, Guangdong, P. R. China

Chunning Zhang
Department of First Tumor, Maoming People's Hospital, Maoming, 525000, Guangdong, P. R. China

Hualiang Lv
Department of Pulmonary and Critical Care Medicine, Maoming People's Hospital, Maoming, 525000, Guangdong, P. R. China

Hanqing Huang
Department of thoracic surgery, Maoming people's Hospital 525000, Guangdong, P. R. China. 5. Department of Clinical Laboratory, Maoming People's Hospital, Maoming, 525000, Guangdong, P. R. China

Xia Ke
Department of Clinical Laboratory, Maoming People's Hospital, Maoming, 525000, Guangdong, P. R. China

Chuchan Zhou
Department Of Clinical Laboratory, Maoming People's Hospital, Maoming, 525000, Guangdong, People's Republic of China

Hao Chen
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 510060, Guangzhou, P. R. China

Shulin Chen
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 510060, Guangzhou, P. R. China

Lei Zhou (zhouleilab@163.com)
Maoming people's hospital  https://orcid.org/0000-0002-5293-867X

Research

Keywords: Lasso-Cox regression model, Prognostic, Nomogram, Nasopharyngeal carcinoma

Posted Date: May 15th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-28083/v1
Abstract

Background

To develop and validate a novel prognostic model to estimate overall survival (OS) in nasopharyngeal carcinoma (NPC) patients based on clinical features and blood biomarkers. And assess its incremental value to TNM staging system, clinical treatment, and Epstein-Barr virus DNA (EBV DNA) for individual OS estimation.

Methods

We retrospectively analyzed 519 consecutive NPC. A prognostic model was generated by using the Lasso-Cox regression model in training cohort (n = 346). Then comparison of predictive accuracy between the novel prognostic model, TNM staging, clinical treatment, and EBV DNA using concordance index (C-index), time-dependent ROC (tdROC), and decision curve analysis (DCA). Subsequently, a nomogram for OS incorporating the prognostic model, TNM staging and clinical treatment was built. Finally, we stratified patients into high-risk and low-risk groups according to the model risk score, and the survival time of these two groups was analyzed using Kaplan–Meier survival plots. All the results were validated in the independent validation cohort (n = 173).

Results

Using the Lasso-Cox regression, a prognostic model was established consisting of 13 variables with respect to patient prognosis. The C-index, tdROC and DCA all showed the prognostic model had good predictive accuracy and discriminatory power than TNM staging, clinical treatment and EBV DNA in training cohort. Nomogram consisting of the prognostic model, TNM staging, clinical treatment and EBV DNA shown some superior net benefit. According to the model risk score, we split the patients into two subgroups: low-risk (risk score ≤ -1.423) and high-risk (risk score > -1.423). There had significant differences in OS between the two subgroups of patients. In the validation cohort, similar results were obtained.

Conclusion

The proposed novel prognostic model based on clinical features and serological markers represents a promising signature for estimating OS in NPC patients.

Background

Nasopharyngeal carcinoma (NPC) is a common malignancy of head and neck in Southern China and Southeast Asia[1]. Distant metastasis is a leading cause of treatment failure in patients with NPC, almost 70% patients are initially diagnosed with locoregionally advanced disease[2]. Although the new radiotherapeutic techniques, chemotherapy regimens, and surgical techniques have improved the survivability of NPC patients, the 5-year survival rate remains unsatisfactory[3].
Currently, the tumor–node–metastasis (TNM) staging system is usually used to aid in determining the prognosis of cancer patients and in suggesting the treatment strategy. However, the NPC patients with the same TNM stage received similar treatment, there were still large patients showed a poor prognosis[4]. Therefore, the TNM staging have some limitations in predicting survival rate of patients with NPC or guiding treatments. This because it is entirely based on the anatomical range of the existing tumors, but not evaluate the intrinsic biological heterogeneity of tumors[5]. Consequently, a lot of biomarkers have been researched to improve the prognosis prediction and treatment efficiency of NPC patients, such as patient clinical characteristics[6], blood biomarkers[7], and radiomics[8]. However, most predictive models are integrated with TNM staging system to improve the predictive accuracy for clinical outcome, which makes them not applicable to the patients with uncertain clinical TNM staging. In addition, some models aren't widely used in clinical practice due to time-consuming, high-cost, high risk of radiation exposure and not routine medical examinations in the majority of primary care hospitals.

Recently, more and more blood biomarkers are used to predict clinical outcome in many cancers because they are benefit us by being cost-effective, higher accessibility and non-invasive, as well as by allowing the simple detection. Thus, the current study sought to construct a novel prognostic model predicts overall survival in NPC patients based on clinical features and routine laboratory blood biomarkers. And assess its incremental value to TNM staging system, clinical treatment, and Epstein-Barr virus DNA (EBV DNA) for individual OS estimation. Finally, we validate its effectiveness in patients from the same institution.

Methods And Materials

Patient selection and data collection

From January 2009 and December 2011, patients with diagnosed NPC who were treated for the first time at Sun Yat-sen University Cancer Center (Guangzhou, China) were retrospectively enrolled in this study. This study was performed in accordance with the guidelines outlined in the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of the Sun Yat-sen University Cancer Center, and all patients provided written informed consent at the first visit to our center. The inclusion criteria for the study are as follows: a: pathological evidence of NPC, were not any malignancies besides NPC; b: complete baseline clinical information, blood-biomarkers data, and follow-up data; c: all the blood-biomarkers data were collected one week before anti-tumor therapy.

The following clinicopathologic data were collected for each enrolled patient: gender, age, family history of malignant tumors, smoking index (SI): day × the year of cigarette smoking[9], body mass index (BMI), TNM staging was assigned according to the 8th AJCC TNM classification[10], and clinical treatment. Relevant baseline blood-biomarkers including white blood cell (WBC), neutrophils (N), lymphocyte (L), monocyte (M), platelet (PLT), hemoglobin (HGB), total protein (TP), albumin (ALB), globulin (GLOB), C-reactive protein (CRP), apolipoprotein AI (APOA), apolipoprotein B (APOB), dehydrogenase (LDH), high density lipoprotein (HDL), cystatin C(Cys-C), plasma EBV DNA copy number (EBV DNA), EBV immunoglobulin A/viral capsid antigen (VCA-IgA), EBV immunoglobulin A/early antigen (EA-IgA), neutrophil to lymphocyte ratio (NLR)[11], derived neutrophil-lymphocyte ratio (dNLR)[12], lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), systemic immune-inflammation index (SII): (platelet × neutrophils) / lymphocyte[13], albumin to globulin
ratio (AGR), C-reactive protein to albumin ratio (CAR), APOA to APOB ratio (ABR), advanced lung cancer inflammation index (ALI): (BMI × albumin) / NLR[14], prognostic nutritional index (PNI): ALB (g/L) + 5 × lymphocyte count × 10^9/L[15], and prognostic index (PI): score 0 for CRP 10 mg/L or less and white cell count 11 × 10^9/L or less, patients with only one of these abnormalities were allocated a score of 1, and if both of them were elevated were allocated a score of 2[16].

Patients follow up

The patients’ survival data follow-up was done by referring to the clinic attendance records, email, and phone calls, all patients were followed-up after discharge until December 2015. The endpoint of this study was overall survival (OS) was defined as the period from the first time of diagnose to the last follow-up or date of patient death.

Statistical analyses

Statistical analyses were performed using IBM SPSS Statistical software version 19.0 (IBMCorp., Chicago, IL, USA) and R version 3.6.0 (http://www.R-project.org). Continuous variables were transformed into categorical variables, and the cut-off value of all variables were recognized by the R package “survival” and “survminer”[17]. Differences in distributions of clinical characteristics and blood-biomarkers between the training cohort and validation cohort were used to Pearson Chi-square test. We utilized the least absolute shrinkage and selection operator (LASSO) regression to select the most useful prognostic factors in the training cohort. According to the regulation weight λ, LASSO selects variables correlated to the measured outcome by shrinking coefficients weights, down to zero for the ones not correlated to outcome[18]. The optimal values of the penalty parameter λ were determined through 10-fold cross-validation with the 1 standard error of the minimum criteria (the 1-SE criteria)[18-19]. Based on the optimal λ value, a list of prognostic variables with associated coefficients was screened out. Then a novel prognostic model was constructed according to calculate the risk score for each patient based on each prognostic variable and its associated coefficient. Comparison of predictive accuracy between the prognostic model, TNM staging, clinical treatment, and EBV DNA for individualized survival was evaluated by concordance index (C-index)[20], time-dependent ROC (tdROC)[21], and decision curve analysis (DCA)[22]. Nomograms (by the package of rms in R) for prediction of OS were built based on prognostic model risk score, TNM staging, clinical treatment, and EBV DNA. The calibration plots of nomograms were used to assess the consistency between the predicted survival and the observed survival with bootstrapping (1000 bootstrap resamples)[23]. Finally, the patients in the training and validation cohort were split into low-risk and high-risk groups according to the optimal cut-off value of prognostic model risk score. Kaplan-Meier method and log-rank tests were used to assess differences in OS between the predicted high- and low-risk groups. Results with two-sided p values of <0.05 were considered statistically significant.

Results

Baseline Clinical and Characteristics

In the present study, 346 eligible patients were analyzed in the training cohort, and 173 patients were included in the validation cohort. The median follow-up was 51.4 months (interquartile range (IQR):42.1 - 67.0) in the training cohort and 50.4 months (IQR: 41.9 - 66.0 months) in the validation cohort. In the training cohort, the 1-
3-, and 5-year OS rates were as follows: 97.4%, 83.8%, and 48.3%. In the validation cohort, the 1-, 3-, and 5-year OS rates were the following: 94.2%, 84.4%, and 42.8%.

The optimal cut-off value for each continuous variable as follows: age (60 years), smoking index (20.0), BMI (26.33 kg/m²), WBC (4.3 × 10⁹/L), Neutrophils (7.0 × 10⁹/L), Lymphocyte (1.41 × 10⁹/L), Monocyte (0.4 × 10⁹/L), Platelet (293.0 × 10⁹/L), HGB (130.0 g/L), NLR (3.91), dNLR (2.46), LMR (3.4), PLR (208.89), SII (1141.96), TP (77.2 g/L), ALB (42.4 g/L), GLOB (33.1 g/L), AGR (1.36), CRP (5.47 mg/L), CAR (0.16), APOA (1.28 g/L), APOB (1.03 g/L), ABR (0.96), LDH (167.5 U/L), HDL (1.16 U/L), Cys-C (0.94 mg/L), ALI (262.33), and PNI (47.35). Patients' clinical characteristics and blood-biomarkers for the patients were listed in Table 1. There was no significant difference in the distribution of clinical characteristics and blood-biomarkers between training cohort and validation cohort.

**Construction of the novel prognostic model**

In order to find the prognostic variables in the training cohort, we used a LASSO-Cox regression analysis model. Figure 1A showed the change in trajectory of each prognostic variable was analyzed. Moreover, we plotted the partial likelihood deviance versus log (λ) in Figure 1B, where λ was the tuning parameter. The value of λ was 0.03987 was chosen by 10-fold cross-validation via the 1-SE criteria. So, we obtained 13 variables with nonzero coefficients at the value λ chosen by cross-validation. These prognostic variables included age, BMI, HGB, PLT, LMR, CRP, CAR, GLOB, AGR, LDH, Cys-C, ALI, and PNI. The coefficients of each prognostic variable were presented in Figure 1C. Then the prognostic model risk score of each patient was computed according to the summation of 13 variables multiplied coefficient from the LASSO regression generated: The prognostic model risk score = -0.680 + (0.569 × age) - (0.280 × BMI + (0.101 ×HGB) - (0.554 × PLT) + (0.197 ×LMR) - (0.199 ×CRP) + (0.186 ×CAR) + (1.248 ×GLOB) - (0.137 ×AGR) - (0.194 ×LDH) + (1.248 × Cys-C) - (0.137 ×ALI) - (0.194 ×PNI).

Where each variable was valued as 0 or 1; a value of 0 was assigned when the variable was less than or equal to the corresponding cut-off value, and a value of 1 otherwise.

**Comparison of predictive accuracy between the novel prognostic model, TNM staging, clinical treatment, and EBV DNA**

As shown in Table 2, in training cohort, the C-index of the prognostic model was 0.786 (95% confidence interval (CI): 0.728-0.844), which was higher than the C-indices of the TNM staging, clinical treatment, and EBV DNA, with values of 0.740 (95% CI: 0.690-0.790), 0.554 (95% CI: 0.521-0.586), and 0.691 (95% CI: 0.623-0.758), respectively. The C-index for the prognostic model was statistically significantly higher than the C-index by the clinical treatment (P < 0.001), and EBV DNA (P = 0.013). In the validation cohort, the C-index of prognostic model was both higher than that of TNM staging and clinical treatment, but it was a little lower than that of EBV DNA. Subsequently, we compared the area under ROC curve (AUC) between the novel prognostic model, TNM staging, clinical treatment, and EBV DNA using tdROC. In general, the AUC of novel prognostic model was higher than others both in the training cohort (Figure 2A) and validation cohort (Figure 2B). Finally, the DCA displayed the prognostic model had a better overall net benefit than TNM staging, clinical treatment and EBV DNA across a wide range of reasonable threshold probabilities in training cohort (Figure 3A) and validation cohort (Figure 3B). These results indicated that the novel prognostic model displayed better accuracy in predicting OS compared with the TNM staging, clinical treatment and EBV DNA.
Building and validating a predictive nomogram

The prognostic model risk score, TNM staging, clinical treatment, and EBV DNA were integrated into nomograms to predict the 1-, 3-, and 5-year OS in the training cohort (Figure 4). Each variable was assigned a corresponding point value based on its contribution to the model. The point values for all the predictor variables are summed to arrive at the “Total Points” axis, and then a line is drawn vertically down from total points to predict the patient’s probability of OS at 1-, 3-, and 5-year. Finally, A calibration plot was used to visualize the performance of the nomogram. Nomogram predicted and actual observed outcome at 1-, 3-, and 5-year OS were plotted on the x-axis and y-axis, respectively. The 45° line represented the best prediction, the solid dark red line represented the performance of the nomograms. The calibration curve showed that the 1-, 3-, and 5-year OS predicted by the nomograms were consistent with actual observations (Figures 5), indicating that the nomograms did well performance. The nomograms and calibration curve in the validation cohort were showed in the supplementary Figure 1 and supplementary Figure 2, respectively.

Survival analyses of NPC patients according to prognostic model risk score

The optimal cut-off value of prognostic model risk score for predicting survival was determined to be -1.423 by R package “survminer” (Figure 6A). According to the cutoff value, we classified patients into two different subgroups, of which low-risk group with risk score ≤ -1.423, and high-risk group with risk score > -1.423. The distribution of the prognostic model risk score in training and validation cohort were showed in Figure 6B and Figure 6C, respectively.

In the training cohort, for the high-risk group, the median OS was 44.4 months (IQR: 24.7 – 66.1) The 1-, 3- and 5-year probabilities of OS were 95.4%, 63.2%, and 33.3%, respectively. For the low-risk group, the median OS was 61.2 months (IQR: 44.6 – 67.8). The 1-, 3- and 5-year probabilities of OS were 98.1%, 90.7% and 53.3%, respectively. In the validation cohort, low-risk group also had higher survival probabilities than high-risk group at 1-, 3-, and 5-year, respectively (Table 3). Kaplan–Meier curves were compared to assess the differences in survival between low-risk and high-risk groups. The results showed statistically significant better OS for low-risk group versus high-risk group both in training cohort and validation cohort (p <0.05; Figure 7).

Discussion

In this study, we successfully established a novel prognostic Lasso-Cox regression model based on clinical features and blood-biomarkers for individualized prediction of the OS for NPC patient. The novel prognostic model showed better predictive accuracy and discrimination compared with the traditional AJCC TNM staging system, clinical treatment, and EBV DNA, which successfully split NPC patients into high-risk and low-risk groups, and the two groups of patients exhibited significant differences in the OS.

The present prognostic model consisting of 13 prognostic variables: age, BMI, HGB, PLT, LMR, CRP, CAR, GLOB, AGR, LDH, Cys-C, ALI, and PNI. All the prognosis variables had been reported to be associated with survival in NPC patients except ALI[24–30], these were credible evidence supporting our analysis results. The ALI was devised to assess the degree of systemic inflammation in patients with advanced non-small cell lung cancer patients[31]. Subsequently, ALI had also been demonstrated to be a prognostic factor of survival in some cancers[32–34]. The difference between the ALI and other inflammatory markers was that the ALI contained
not only indices related to inflammation but also the body mass index (BMI), which was reported to correlate with the sarcopenic status[33]. So, this was the first study to indicate ALI as a prognostic marker in NPC patients.

Subsequently, we compared the predictive accuracy and discrimination of the novel prognostic model with TNM staging, clinical treatment and EBV DNA using C-index, tdROC and DCA. The results all showed the prognostic model had good predictive accuracy and discriminatory power than TNM staging, clinical treatment and EBV DNA in training cohort. Above similar results were observed in the validation cohort except EBV DNA. The C-index of the prognostic model was slightly lower than EBV DNA, but there was no statistical difference. The most likely explanation was that this was a retrospective analysis, and there may have some potential patient selection bias. Then the nomogram consisting of the prognostic model, TNM staging, clinical treatment and EBV DNA shown some superior net benefit. Finally, according to the model risk score, we split the patients into two subgroups: low-risk and high-risk, and there were significant differences in OS between the two subgroups of patients. These results indicated the novel prognostic model had good predictive accuracy and discrimination for estimating OS in NPC patients.

Although previous studies had established some models for predicting NPC survival, this study still had several merits compared to other studies: 1. The prognostic model only included basic clinical and routine laboratory data, which did not include some not routinely available markers, such as EBV DNA[35], and circulating tumor cells (CTC)[36–37]. and this model was low-cost, non-invasive, no risk of radiation exposure, and convenient. So, this model could widely and safely used in clinical practice, especially in primary hospitals. 2. The prognostic model was constructed by using the newly algorithm LASSO-Cox model, as a statistical method for screening variables to establish the prognostic model, which enabled to adjust for model's over fitting and avoid extreme predictions. So, the predictive accuracy could be improved significantly, and this approach had been applied in many study[18, 38–39]. 3. Many previous models usual integrated with TNM staging and/or clinical treatment to improve the predictive accuracy for clinical outcome[27, 40–45], which made them not applicable to the patients with uncertain clinical TNM staging. This model can be used for patients with TNM staging remained unclear because of it was not include TNM staging.

There also had several drawbacks of this study. First, this was a retrospective analysis and selection bias might exist. Second, the treatment effect heterogeneity for metachronous metastasis patients might bring confounding effects. Third, the endpoint of this study was OS, and the effect of the model for predicting disease-free survival (DFS), distant metastasis free survival (DMFS) and locoregional relapse-free survival (LRFS) in NPC patients were not assessed[46]. It was better clinical application that the endpoint combined OS with DFS and DMFS. Finally, it was a single-institutional study with a relatively small sample size. Thus, a large-scale and multicenter validation of the model will be needed in the future.

**Conclusion**

In conclusion, we have established a novel prognostic model based on clinical features and blood biomarkers, which showed better predictive accuracy than traditional TNM staging, clinical treatment, and EBV DNA, and the nomograms comprising the prognostic model, TNM staging, clinical treatment, and EBV DNA can reinforce the prognostic ability of the prognostic model. Therefore, the simple, convenient, low-cost, non-invasive, no risk
of radiation exposure, precise and understandable prognostic model was useful for clinicians in decision-making, individual patient counselling and scheduling patients’ follow-ups for NPC patients.

Declarations

Authors’ Contributions

All authors contributed to this manuscript, including conception and design (HC, SLC, LZ), acquisition of data (HC), analysis and interpretation of data (CCL, CNZ), material support (SLC), study supervision (HLL, HQH, XK, CCZ), and writing, review and revision of the manuscript (CCL, CNZ, HLL, HQH, XK, CCZ, HC, SLC, LZ).

Acknowledgments

We thank Sun Yat-sen University Cancer Center for providing support on research conditions in this study, and high-level hospital construction research project of Maoming people’s hospital.

Conflict of interest

The authors of this manuscript have no potential conflicts of interest to declare.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved by the Clinical Research Ethics Committee of the Sun Yat-sen University Cancer Center, and all patients provided written informed consent at the first visit to our center.

Funding

This work was supported by the Natural Science Foundation of Guangdong Province (2018A030313622), funded by the Open Project Program of the State Key Laboratory of Proteomics (SKLPO201703), and high-level hospital construction research project of Maoming people’s hospital.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. OuYang PY, Su Z, Ma XH, Mao YP, Liu MZ, Xie FY. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer. 2013;109:2987–97.

3. Wang WY, Twu CW, Chen HH, Jan JS, Jiang RS, Chao JY, Liang KL, Chen KW, Wu CT, Lin JC. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010;16:1016–24.

4. Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388:1883–92.

5. Ng WT, Yuen KT, Au KH, Chan OS, Lee AW. Staging of nasopharyngeal carcinoma—the past, the present and the future. Oral Oncol. 2014;50:549–54.

6. Wang S, Ge M, Wang K, Lou J, Chen X. The clinical features and prognosis of radiotherapy associated sarcoma (RAS) following radiotherapy for nasopharyngeal carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;49:955–8.

7. Janvilisri T. Omics-based identification of biomarkers for nasopharyngeal carcinoma. Dis Markers. 2015;2015:762128.

8. Zhang B, Tian J, Dong D, Gu D, Dong Y, Zhang L, Lian Z, Liu J, Luo X, Pei S, et al. Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma. Clin Cancer Res. 2017;23:4259–69.

9. Tokarskaya ZB, Scott BR, Zhuntova GV, Okladnikova ND, Belyaeva ZD, Khokhryakov VF, Schollnberger H, Vasilenko EK. Interaction of radiation and smoking in lung cancer induction among workers at the Mayak nuclear enterprise. Health Phys. 2002;83:833–46.

10. OuYang PY, Xiao Y, You KY, Zhang LN, Lan XW, Zhang XM, Xie FY: Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 2017, 72:65–72.

11. Liao LJ, Hsu WL, Wang CT, Lo WC, Cheng PW, Shueng PW, Hsieh CH, Chiu YL, Lin YC. Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in nasopharyngeal carcinoma: A retrospective study of 180 Taiwanese patients. Clin Otolaryngol. 2018;43:463–9.

12. Zhao L, Chen H, Hu B, Zhang H, Lin Q. Prognostic significance of Ki67 expression and the derived neutrophil-lymphocyte ratio in nasopharyngeal carcinoma. Cancer Manag Res. 2018;10:1919–26.

13. Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23:6261–72.

14. Ozyurek BA, Ozdemirel TS, Ozden SB, Erdogan Y, Ozmen O, Kaplan B, Kaplan T. Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer? Clin Respir J. 2018;12:2013–9.

15. He X, Li JP, Liu XH, Zhang JP, Zeng QY, Chen H, Chen SL. Prognostic value of C-reactive protein/albumin ratio in predicting overall survival of Chinese cervical cancer patients overall survival: comparison among various inflammation based factors. J Cancer. 2018;9:1877–84.

16. Kasymjanova G, Macdonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H, Sharma R, Small D. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Current Oncology. 2010;17:52–8.
17. Diboun I, Wernisch L, Orengo CA, Koltzenburg M. Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genom. 2006;7:252.

18. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16:385–95.

19. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J. 2010;52:70–84.

20. Brentnall AR, Cuzick J. Use of the concordance index for predictors of censored survival data. Stat Methods Med Res. 2018;27:2359–73.

21. Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. 2017;17:53.

22. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.

23. Shim JH, Jun MJ, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261:939–46.

24. Du XJ, Tang LL, Mao YP, Sun Y, Zeng MS, Kang TB, Jia WH, Lin AH, Ma J. The pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinoma. PloS one. 2014;9:e94473.

25. Zeng Q, Hong MH, Shen LJ, Meng XQ, Guo X, Qian CN, Wu PH, Huang PY. Nomograms for predicting long-term survival in patients with non-metastatic nasopharyngeal carcinoma in an endemic area. Oncotarget. 2016;7:29708–19.

26. Hu JY, Yi W, Xia YF, Gao J, Liu ZG, Tao YL. Impact of pretherapy body mass index on prognosis of nasopharyngeal carcinoma. Ai Zheng. 2009;28:1043–8.

27. Li J, Chen S, Peng S, Liu Y, Xing S, He X, Chen H. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Biol Sci. 2018;14:549–56.

28. Li JP, Chen SL, Liu XM, He X, Xing S, Liu YJ, Lin YH, Liu WL. A Novel Inflammation-Based Stage (I Stage) Predicts Overall Survival of Patients with Nasopharyngeal Carcinoma. Int J Mol Sci 2016, 17.

29. Du XJ, Tang LL, Mao YP, Guo R, Sun Y, Lin AH, Ma J. Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. J Transl Med. 2015;13:364.

30. Yuan J, Xu M, Li J, Li N, Chen LZ, Feng QS, Zeng YX. Prognostic value of cystatin C in patients with nasopharyngeal carcinoma: a retrospective study of 1063 patients. Clinics. 2016;71:338–43.

31. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158.

32. Park YH, Yi HG, Lee MH, Kim CS, Lim JH. Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy. Acta Haematol. 2017;137:76–85.
33. Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kimura K, Amano R, Hirakawa K, Ohira M. The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study. BMC Cancer. 2019;19:241.

34. Hua X, Chen J, Wu Y, Sha J, Han S, Zhu X. Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis. World J Surg Oncol. 2019;17:177.

35. Lertbutsayanukul C, Kannarunimit D, Prayongrat A, Chakkabat C, Kitpanit S, Hansasuta P. Prognostic Value of Plasma EBV DNA for Nasopharyngeal Cancer Patients during Treatment with Intensity-modulated Radiation Therapy and Concurrent Chemotherapy. Radiol Oncol. 2018;52:195–203.

36. You R, Liu YP, Lin M, Huang PY, Tang LQ, Zhang YN, Pan Y, Liu WL, Guo WB, Zou X, et al. Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients. Int J Cancer. 2019;145:2873–83.

37. Ou G, Xing S, Li J, Zhang L, Chen S. Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma. Mol Med. 2019;25:50.

38. Moons KG, Donders AR, Steyerberg EW, Harrell FE. Penalized maximum likelihood estimation to directly adjust diagnostic and prognostic prediction models for overoptimism: a clinical example. J Clin Epidemiol. 2004;57:1262–70.

39. Srivastava S, Chen L. Comparison between the stochastic search variable selection and the least absolute shrinkage and selection operator for genome-wide association studies of rheumatoid arthritis. BMC Proc. 2009;3(Suppl 7):21.

40. Xia WX, Zhang HB, Shi JL, Lu X, Wang L, Ye YF, Cao KJ, Qian CN, Guo X, Xiang YQ. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment serum C-reactive protein and N-classification. Eur J Cancer. 2013;49:2152–60.

41. Chang H, Gao J, Xu BQ, Guo SP, Lu RB, Li G, Huang SM, Han F, Liu ZG, Tao YL, et al. Haemoglobin, neutrophil to lymphocyte ratio and platelet count improve prognosis prediction of the TNM staging system in nasopharyngeal carcinoma: development and validation in 3,237 patients from a single institution. Clin Oncol (R Coll Radiol). 2013;25:639–46.

42. Zhang H, Xia W, Lu X, Sun R, Wang L, Zheng L, Ye Y, Bao Y, Xiang Y, Guo X. A novel statistical prognostic score model that includes serum CXCL5 levels and clinical classification predicts risk of disease progression and survival of nasopharyngeal carcinoma patients. PloS one. 2013;8:e57830.

43. Liang W, Shen G, Zhang Y, Chen G, Wu X, Li Y, Li A, Kang S, Yuan X, Hou X, et al. Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment. Chin J Cancer. 2016;35:98.

44. Yang L, Hong S, Wang Y, Chen H, Liang S, Peng P, Chen Y. Development and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy. Sci Rep. 2015;5:15638.

45. Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, Lai XP, He Y, Xu YX, Hu DP, et al: Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst 2016, 108.

46. Yang S, Fu X, Huang G, Chen J, Luo S, Wang Z, Kong F, Wu G, Lin S, Wang F, Chen L. The impact of the interval between the induction of chemotherapy and radiotherapy on the survival of patients with
Table 1. Demographics and clinical characteristics of patients in the training and validation cohort
| Characteristic | Training cohort | Validation cohort | \( \chi^2 \) value | \( P \) value |
|---------------|-----------------|-------------------|-------------------|-------------|
| Gender        |                 |                   |                   |             |
| Male          | 264 (76.3%)     | 121 (69.9%)       | 2.435             | 0.119       |
| Female        | 82 (23.7%)      | 52 (30.1%)        |                   |             |
| Age (years)   |                 |                   |                   |             |
| \( \leq 60 \) | 310 (89.6%)     | 150 (86.7%)       | 0.956             | 0.328       |
| \( >60 \)    | 36 (10.4%)      | 23 (13.3%)        |                   |             |
| Family history|                 |                   |                   |             |
| Yes           | 90 (26.0%)      | 47 (27.2%)        | 0.079             | 0.778       |
| No            | 256 (74.0%)     | 126 (72.8%)       |                   |             |
| Smoking index |                 |                   |                   |             |
| \( \leq 20.0 \) | 226 (65.3%) | 103 (59.5%) | 1.661             | 0.198       |
| \( >20.0 \)  | 120 (34.7%)     | 70 (40.5%)        |                   |             |
| BMI (kg/m\(^2\)) |            |                   |                   |             |
| \( \leq 26.33 \) | 298 (86.1%) | 155 (89.6%) | 1.250             | 0.264       |
| \( >26.33 \)  | 48 (13.9%)      | 18 (10.4%)        |                   |             |
| TNM stage\(b\) |             |                   |                   |             |
| I             | 12 (3.5%)       | 5 (2.9%)          | 1.965             | 0.580       |
| II            | 45 (13.0%)      | 24 (13.9%)        |                   |             |
| III           | 172 (49.7%)     | 76 (43.9%)        |                   |             |
| IV            | 117 (33.8%)     | 68 (39.3%)        |                   |             |
| Treatment     |                 |                   |                   |             |
| Rad           | 58 (16.8%)      | 32 (18.5%)        | 0.242             | 0.623       |
| Rad and Che   | 288 (83.2%)     | 141 (81.5%)       |                   |             |
| WBC (10\(^9\)/L) |             |                   |                   |             |
| \( \leq 4.3 \) | 57 (16.5%)      | 29 (16.8%)        | 0.007             | 0.933       |
| \( >4.3 \)   | 289 (83.5%)     | 144 (83.2%)       |                   |             |
| Neutrophils (10\(^9\)/L) |           |                   |                   |             |
| \( \leq 7.0 \) | 306 (88.4%)   | 148 (85.5%)       | 0.879             | 0.348       |
| \( >7.0 \)   | 40 (11.6%)      | 25 (14.5%)        |                   |             |
| Lymphocyte (10\(^9\)/L) |         |                   |                   |             |
| \( \leq 1.41 \) | 145 (41.9%) | 75 (43.4%) | 0.099             | 0.753       |
| \( >1.41 \)  | 201 (58.1%)     | 98 (56.6%)        |                   |             |
| Monocyte (10\(^9\)/L) |           |                   |                   |             |
| \( \leq 0.4 \) | 175 (50.6%)    | 82 (47.4%)        | 0.466             | 0.495       |
| \( >0.4 \)   | 171 (49.4%)     | 91 (52.6%)        |                   |             |
| Platelet (10\(^9\)/L) |          |                   |                   |             |
| \( \leq 293.0 \) | 298 (86.1%) | 154 (89.0%) | 0.857             | 0.355       |
| \( >293.0 \)  | 48 (13.9%)      | 19 (11.0%)        |                   |             |
| HGB (g/L)     |                 |                   |                   |             |
| \( \leq 130.0 \) | 106 (30.6%) | 61 (35.3%) | 1.130             | 0.288       |
| \( >130.0 \)  | 240 (69.4%)     | 112 (64.7%)       |                   |             |
| NLR           |                 |                   |                   |             |
| \( \leq 3.91 \) | 263 (76.0%)   | 126 (72.8%)       | 0.621             | 0.431       |
| \( >3.91 \)  | 83 (24.0%)      | 47 (27.2%)        |                   |             |
| dNLR          |                 |                   |                   |             |
| \( \leq 2.46 \) | 254 (73.4%)   | 121 (69.9%)       | 0.692             | 0.405       |
| \( >2.46 \)  | 92 (26.6%)      | 52 (30.1%)        |                   |             |
| LMR           |                 |                   |                   |             |
| \( \leq 3.4 \) | 141 (40.8%)    | 76 (43.9%)        | 0.479             | 0.489       |
| \( >3.4 \)   | 205 (59.2%)     | 97 (56.1%)        |                   |             |
| PLR           |                 |                   |                   |             |
| \( \leq 208.89 \) | 277 (80.1%) | 140 (80.9%) | 0.055             | 0.815       |
| \( >208.89 \) | 69 (19.9%)      | 33 (19.1%)        |                   |             |
| SII           |                 |                   |                   |             |
| \( \leq 1141.96 \) | 294 (85.0%) | 144 (83.2%) | 0.263             | 0.608       |
| \( >1141.96 \) | 52 (15.0%)     | 29 (16.8%)        |                   |             |
| TP (g/L)      |                 |                   |                   |             |
| \( \leq 77.2 \) | 273 (78.9%)   | 128 (74.0%)       | 1.585             | 0.208       |
| \( >77.2 \)  | 73 (21.1%)      | 45 (26.0%)        |                   |             |
| ALB (g/L)     |                 |                   |                   |             |
| \( \leq 42.4 \) | 132 (38.2%)   | 63 (36.4%)        | 0.148             | 0.701       |
| \( >42.4 \)  | 214 (61.8%)     | 110 (63.6%)       |                   |             |
| GLOB (g/L)    |                 |                   |                   |             |
| \( \leq 33.1 \) | 274 (79.2%)   | 139 (80.3%)       | 0.095             | 0.758       |
| \( >33.1 \)  | 72 (20.8%)      | 34 (19.7%)        |                   |             |
| AGR           |                 |                   |                   |             |
| \( \leq 1.36 \) | 108 (30.6%)   | 45 (26.0%)        | 1.406             | 0.236       |
| \( >1.36 \)  | 240 (69.4%)     | 128 (74.0%)       |                   |             |
| CRP (mg/L)    |                 |                   |                   |             |
| \( \leq 0.87 \) |             | 0.087             | 0.768             |             |
a: Smoking index: the number of cigarettes smoked each day × the year of cigarette smoking;
b: TNM stage was classified according to the AJCC 8th TNM staging system;
Abbreviations: BMI: body mass index; TNM: Tumor Node Metastasis stage; Rad: radiotherapy; Che: chemotherapy; WBC: white blood cell; HGB: hemoglobin; NLR: neutrophil/lymphocyte ratio; dNLR: neutrophil/WBC-neutrophil ratio; LMR: lymphocyte/monocyte ratio; PLR: platelet/lymphocyte ratio; SII: systemic immune-inflammation index; TP: total protein; ALB: albumin; GLOB: globulin; AGR: ALB/GLOB ratio; CRP: C-reactive protein; CAR: C-reactive protein/albumin ratio; APOA: apolipoprotein AI; APOB: apolipoprotein B; ABR: APOA/APOB ratio; LDH: lactic dehydrogenase; HDL: high density lipoprotein; Cys-C: cystatin C; EBV: Epstein-Barr virus; VCA-IgA: EBV immunoglobulin A/viral capsid antigen; EA-IgA: EBV immunoglobulin A/early antigen; ALI: advanced lung cancer inflammation index; PNI: prognostic nutritional index; PI: prognostic index.

Table 2. The C-index of the prognostic model, TNM staging, Treatment, and EBV DNA for prediction of OS in the training cohort and validation cohort
| Factors                          | C-index (95% CI)     | P       |
|---------------------------------|----------------------|---------|
| For training cohort             |                      |         |
| Prognostic model                | 0.786 (0.728–0.844)  |         |
| TNM staging                     | 0.740 (0.690–0.790)  |         |
| Treatment                       | 0.554 (0.521–0.586)  |         |
| EBV DNA                         | 0.691 (0.623–0.758)  |         |
| Prognostic model vs TNM staging | 0.067                |         |
| Prognostic model vs Treatment   | <0.001               |         |
| Prognostic model vs EBV DNA     | 0.013                |         |
| For validation cohort           |                      |         |
| Prognostic model                | 0.697 (0.612–0.734)  |         |
| TNM staging                     | 0.655 (0.575–0.734)  |         |
| Treatment                       | 0.529 (0.470–0.588)  |         |
| EBV DNA                         | 0.734 (0.659–0.813)  |         |
| Prognostic model vs TNM staging | 0.310                |         |
| Prognostic model vs Treatment   | <0.001               |         |
| Prognostic model vs EBV DNA     | 0.511                |         |

C-index = concordance index; CI = confidence interval; P values are calculated based on normal approximation using function rcorr.cens in Hmisc package.

Table 3. OS and OS rate in high-risk and low-risk groups according to the model risk score in the training and validation cohort

| Parameter          | Training cohort |                  | Validation cohort |                  |
|--------------------|-----------------|------------------|-------------------|------------------|
|                    | High-Risk Group | Low-Risk Group   | Total             | High-Risk Group | Low-Risk Group   | Total             |
| No. of patients    | 87              | 259              | 346               | 49              | 124              | 173               |
| Median (IQR)       | 44.4 (24.7–66.1)| 61.2 (44.6–67.8)| 51.4 (42.1–67.0)| 45.8 (26.1–64.1)| 53.5 (43.0–66.3)| 50.4 (41.9–66.0)|
| No. of OS 1-Year   | 83 (95.4%)      | 254 (98.1%)     | 337 (97.4%)       | 44 (89.8%)      | 119 (96.0%)      | 163 (94.2%)       |
| 3-Year             | 55 (63.2%)      | 235 (90.7%)     | 290 (83.8%)       | 36 (73.5%)      | 110 (88.7%)      | 146 (84.4%)       |
| 5-Year             | 29 (33.3%)      | 138 (53.3%)     | 167 (48.3%)       | 17 (34.7%)      | 57 (46.0%)       | 74 (42.8%)        |

Abbreviations: OS: overall survival; IQR: interquartile range.

**Supplemental Figure Legends**

**Supplementary Figure 1:** The nomograms was used to estimate OS for NPC patients in validation cohort

**Supplementary Figure 2:** The calibration plot for the nomograms at 1-, 3-, 5-year in validation cohort.

**Figures**
Figure 1

Potential predictors selection using LASSO-Cox regression model.
Figure 2

Comparison of predictive accuracy between prognostic model, TNM staging, and clinical treatment using time dependent ROC curves in training cohort and validation cohort.

Figure 3

Decision curve analysis for each model in training cohort and validation cohort.
Figure 4

The nomogram was used to estimate OS for NPC patients in training cohort.
Figure 5

The calibration plot for the nomograms at 1-, 3-, 5- year in training cohort.
Figure 6

The optimal cut-off value of prognostic model risk score using R package "survival", and the distribution of the prognostic model risk score in training cohort and validation cohort.

Figure 7

Kaplan–Meier analyses of OS according to the prognostic model risk score classifier in subgroups of NPC patients in training cohort and the validation cohort.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementFigure2.tif
